Multi-component nutritional supplement
Multi-component nutritional supplement has been studied in 2 papers since 2024: 2 trials in people; 1 in the past year. The newest paper, Jan 21, 2026: “Developing a multicomponent nturitional supplement to enhance cognitive function in older adults-- a precision biomarker analysis”.
2 papers study it8 findingsUpdated
See all 2 papers on multi-component nutritional supplement
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country; 1 trial, none about aging.
“No significant effect of the supplement was observed for GDF-15, a marker linked to aging.”
2 of its findings point the other way.
- 1 lab in 1 country
- 2 findings against
- 1 trial, none about aging
- Funders: Bayer and 2 more
- 8 of 8 findings with company ties
- Human trial2
Studies in people
1 study gave multi-component nutritional supplement to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases InflammAge-4.055% no change: Has no effect on Horvath clock down: Decreases C-reactive protein-28.3% | Trial12 weeks | 83 people31 males, 52 females72.2 ± 6.4 yearsHealthy older adults aged ≥ 60 years | GeroScience, Mar 26, 2024 |
What did studies of multi-component nutritional supplement find?
5Studies of multi-component nutritional supplement measured 5 outcomes, among them C-reactive protein, epigenetic age and GDF-15.
C-reactive protein
no changein humans1downin humans1−28%
1 study
C-reactive protein
no changein humans1downin humans1−28%
Multi-component nutritional supplement showed no clear effect on C-reactive protein in all participants.
“No differences were observed pre- and post-treatment in plasma GDF-15 and CRP”
Human trialin all participantsplasma12-week
GeroScience
Multi-component nutritional supplement decreases C-reactive protein in participants with hsCRP of 3 μg/ml or more at baseline (p = 0.0195).
“participants with CRP indicative of an elevated cardiovascular disease risk (hsCRP ≥ 3μg/ml), had a reduction in CRP post-supplementation (p = 0.0195)”
Human trialin participants with hsCRP of 3 μg/ml or more at baseline12-week
GeroScience
Multi-component nutritional supplement decreases C-reactive protein in the higher CVD risk group (baseline CRP ≥ 3 μg/ml) (-28.3%).
“revealed a significant 28.3% decline in CRP levels following treatment in the nine participants in the high-risk group compared with V1 (p < 0.0195; Table”
Human trialin the higher CVD risk group (baseline CRP ≥ 3 μg/ml)12 weeksn = 9
GeroScience
Epigenetic age
no changein humans1downin humans1
1 study
Epigenetic age
no changein humans1downin humans1
Multi-component nutritional supplement showed no clear effect on epigenetic age in all participants.
“No difference between the epigenetic and chronological ages of participants was observed pre- and post-treatment by the blood-based Horvath or Hannum clocks”
Human trialin all participantswhole blood12-week
GeroScience
Multi-component nutritional supplement decreases epigenetic age in participants with epigenetic age acceleration of 2 years or more at baseline (p = 0.015; p = 0.0058).
“a significant reduction in epigenetic age (p = 0.015) and epigenetic age acceleration (p = 0.0058) was observed post-treatment”
Human trialin participants with epigenetic age acceleration of 2 years or more at baselinesaliva12-week
GeroScience
GDF-15
no changein humans1
1 study
GDF-15
no changein humans1
Multi-component nutritional supplement showed no clear effect on GDF-15 in humans.
“No significant effect of the supplement was observed for GDF-15, a marker linked to aging.”
Human trial12 weeksn = 83
GeroScience
Horvath clock
no changein humans1
1 study
Horvath clock
no changein humans1
Multi-component nutritional supplement showed no clear effect on Horvath clock in humans.
“Further analysis examining the difference in Hannum and Horvath epigenetic age acceleration of participants pre and post nutraceutical treatment revealed no significant change in participant epigenetic age acceleration following treatment, for either clock (Fig. C and D, respectively).”
Human trial12 weeks
GeroScience
InflammAge
downin humans1−4.1%
1 study
InflammAge
downin humans1−4.1%
Multi-component nutritional supplement decreases InflammAge in participants with baseline InflammAge ≥ 2 years higher than chronological age (-4.055%).
“The supplement reduced the InflammAge score in this group by 4.055%, equivalent to 3.31 years, (p = 0.015; Fig. B) and the degree of InflammAge acceleration by 46.77%, equivalent to 3.47 years, (p = 0.0058; Fig. D).”
Human trialin participants with baseline InflammAge ≥ 2 years higher than chronological age12 weeksn = 29
GeroScience
Has multi-component nutritional supplement been tested in people?
0 of 1 about agingYes: 2 trials in people have been published, and 1 trial is registered.
In trials
No phaseCompleted1 trial
No phaseCompleted1 trial
No phaseCompleted1 trial
No phaseCompleted1 trial
Trial sponsors
Company1 trial70 people